PEG-MGF
PEGylated Mechano Growth Factor
The MGF E-domain partially activates the IGF-1 receptor. This signaling stimulates activation and proliferation of Pax7-positive satellite cells, the stem-cell population of muscle. Proposed effects include local tissue repair, hypertrophy and formation of new blood vessels, without the systemic metabolic actions associated with IGF-1.
Not medical advice. Educational reference only.
- Typical dose
- 100 mcg, once daily, subcutaneous injection; 250 mcg, once daily, subcutaneous injection; 200–400 mcg, 1–2 times weekly, injectable (route unspecified)
- Route
- Subcutaneous injection (100 mcg and 250 mcg daily schedules); injectable, route unspecified (200–400 mcg schedule)
- Storage
- Keep refrigerated at 2–8°C and use within 28 days.
What is PEG-MGF?
PEG-MGF is mechano growth factor modified by the addition of polyethylene glycol. MGF itself is a locally produced IGF-1 splice variant that muscle generates following injury or mechanical loading. PEGylation lengthens its persistence from minutes to roughly five days. Research examines muscle satellite-cell activation, muscle enlargement and repair. PEG-MGF remains a research compound without FDA approval.
Mechanism of action
The MGF E-domain partially activates the IGF-1 receptor. This signaling stimulates activation and proliferation of Pax7-positive satellite cells, the stem-cell population of muscle. Proposed effects include local tissue repair, hypertrophy and formation of new blood vessels, without the systemic metabolic actions associated with IGF-1.
Targets: IGF-1 receptor (IGF1R) · Muscle satellite cells (Pax7+)
Research indications
Tissue Repair
Most effectiveExperimental findings suggest quicker wound closure and restoration of damaged soft tissues.
Gut Health
EffectiveResearch investigates benefits for the intestinal barrier and gastrointestinal function.
Joint Support
EffectivePotential joint benefits include less inflammation and greater ease of movement.
Muscle Recovery
ModerateResearch considers whether recovery from muscle strain and exercise-related stress can be accelerated.
Research protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Amount | Frequency | Route |
|---|---|---|---|
| Starting Dose | 100 mcg | Once daily | Subcutaneous injection |
| Standard Dose | 250 mcg | Once daily | Subcutaneous injection |
| Additional research schedule | 200–400 mcg | 1–2 times weekly | Injectable |
Interactions
TB-500 / BPC-157
CompatibleNSAIDs (Ibuprofen, Naproxen)
CautionCorticosteroids
CautionAnticoagulants
MonitorGH Secretagogues
CompatibleNAD+
Compatible
How to reconstitute and inject
Diluent: Use bacteriostatic water; avoid saline because it may cause precipitation.
- Let your refrigerated PEG-MGF vial warm to room temperature for 15–20 minutes before preparation.
- Disinfect the vial’s rubber closure with an alcohol wipe, then wait until it has dried completely.
- Use a sterile syringe to measure the calculated amount of bacteriostatic water. Avoid saline because precipitation may occur.
- Add the water slowly against the vial’s inner wall. Keep the stream away from the dry powder itself.
- Rotate the vial gently to mix its contents. Do not shake forcefully, because this can damage the peptide.
- Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is transparent and has no color.
- Measure your calculated subcutaneous dose with an insulin syringe after dissolution.
- Choose the abdomen, upper arm or thigh for injection. Alternate the injection location each time to help prevent lipodystrophy.
- Refrigerate the mixed solution at 2–8°C, and discard any remainder after 28 days. Use these steps only for an appropriate research formulation; follow the specific product instructions for prescription presentations.
What to expect
- Week 1–2
- Early anti-inflammatory activity may reduce pain and swelling around the affected tissue.
- Week 2–4
- Tissue movement may become easier and discomfort may lessen as healing begins to accelerate.
- Week 4–8
- More substantial recovery may include improved tissue repair and better function.
- Week 8–12
- Healing may approach completion in some cases, with stronger tissue and better structural integrity. These research expectations are not established human recovery guarantees.
Side effects and safety
- Mild nausea at higher doses
- Local redness or discomfort following injection
- Dizziness or a lightheaded sensation · Rare
- Possible changes in blood pressure; monitor if you have hypertension
PEG-MGF: not approved in the US.
Regulatory status
US
Not approvedFDA — No US approval. Research use does not constitute approval for treatment in humans.
- Rx required
- No
- Telehealth
- N/A
Frequently asked questions
How should research dosing be interpreted?
Research doses depend on the goal and route of administration. The schedules are educational descriptions, not personal dosing instructions. Consult a qualified healthcare professional about the relevant indication and current literature before considering use.
What should you know about unwanted effects?
Adverse effects can differ according to dose, administration route and individual response. Begin only at the lowest clinician-directed amount and monitor your response carefully. Seek advice before use, and report any unusual symptoms to your healthcare professional. Human safety is not fully characterized for experimental applications.
How does PEGylation change MGF?
Adding polyethylene glycol increases the approximate half-life from minutes to five days. Research examines activation of muscle satellite cells and support for muscle growth and repair. The additional injectable schedule is 200–400 mcg administered 1–2 times each week; it is separate from the daily subcutaneous schedules. PEG-MGF is generally well tolerated in research settings, although that does not establish long-term human safety.
References
Mechano growth factor E peptide (MGF-E), a muscle-specific splice variant of IGF-1 (2004)